Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Balloon Sinuplasty Effective for Treating Chronic Sinusitis

By HospiMedica International staff writers
Posted on 13 Oct 2008
Follow-up studies of balloon sinuplasty patients confirm that sinuplasty technology is safe and effective when used to treat chronic sinusitis patients. More...


Researchers at the Georgia Nasal and Sinus Institute (Savannah, USA) and the Sinus Center of the South (Biloxi, MS, USA) conducted one and two year follow-ups of 109 patients who had minimally invasive sinus surgery using balloon sinuplasty technology that were performed in 2005; all patients had participated previously in the Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR) study. Patients were prospectively evaluated by Sinonasal Outcome Test (SNOT-20) and computed tomographic (CT) scan. The studies found that 92% of the patients had functional patency of the cleared drainage channels at one-year follow-up; at two-year follow-up, 85% of patients reported improvement in their sinus symptoms. No patient's condition worsened, and clinically and statistically significant improvements in their quality of life were maintained at one and two year follow-up. No serious adverse events observed at any time point throughout the studies. Both studies were published in the September 2008 issue of Otolaryngology - Head and Neck Surgery.

"These multi-year data continue to affirm the safety and effectiveness of balloon sinuplasty technology. Patients can feel confident that this technology truly provides significant, durable improvement in sinus symptoms and overall quality of life,” said lead author of the two-year study and co-author of the one-year study, otolaryngologist Raymond Weiss, M.D. of the Sinus Center of the South.

Balloon Sinuplasty technology, developed by Acclarent (Menlo Park, CA, USA) is used to restore normal sinus drainage by widening constricted passages with balloons using an endoscopic, catheter-based system, and can be used alone or in conjunction with standard surgical instrumentation. There is little or no damage to nasal mucosa or to the ostia of the sinus. Recovery times vary after sinus surgery, but patients typically return to normal activities within 24 hours of treatment.

Related Links:
Sinus Center of the South
Acclarent


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.